Insights
New Oral Direct Anticoagulants (NOACs) offer a safer alternative to warfarin for elderly patients at risk of stroke. These medications, including dabigatran, rivaroxaban, apixaban, and edoxaban, reduce bleeding risks and avoid regular lab monitoring.
Area of Science:
- Geriatrics
- Pharmacology
- Cardiology
Background:
- Elderly and fragile patients face elevated risks of atrial fibrillation and systemic embolism, necessitating anticoagulation.
- These patients also exhibit increased bleeding risks due to age and comorbidities, complicating traditional anticoagulation.
- Warfarin has been the standard, but new oral direct anticoagulants (NOACs) present a viable alternative.
Purpose of the Study:
- To evaluate the role and optimal use of NOACs in elderly and fragile patients.
- To compare the safety and efficacy profiles of dabigatran, rivaroxaban, apixaban, and edoxaban in this demographic.
- To inform individualized anticoagulation strategies for seniors, considering reduced doses where appropriate.
Main Methods:
- Review of pharmacological properties and registration studies of NOACs (dabigatran, rivaroxaban, apixaban, edoxaban).
- Analysis of patient characteristics in geriatrics, including reduced body weight, renal function, and comorbidities.
- Consideration of benefit-risk assessment in elderly patients undergoing anticoagulation therapy.
Main Results:
- NOACs do not require regular laboratory monitoring, a significant advantage over warfarin.
- NOACs are associated with a reduced risk of intracranial hemorrhage compared to traditional anticoagulants.
- Individual NOACs possess specific properties allowing for tailored anticoagulation strategies.
- Reduced doses of NOACs may be advantageous for a subset of elderly patients.
Conclusions:
- NOACs represent a safer and more convenient anticoagulation option for elderly and fragile patients.
- Individualized treatment selection and dose adjustment are crucial for optimizing NOAC therapy in seniors.
- Ongoing benefit-risk assessment is essential throughout the anticoagulation therapy in this vulnerable population.
Abstract:
Elderly and fragile patients have a higher risk of atrial fibrillation, a higher risk of systemic embolism. They are therefore often candidates for long-term anticoagulation medication. At the same time, they have an increased risk of bleeding due to age and co-morbidities, which anticoagulation therapy necessarily potentiates. New Oral Direct Anticoagulants (NOAC) registered in the Czech Republic - dabigatran, rivaroxaban, apixaban or edoxaban - are a good alternative to the currently dominant warfarin in many of these indications. Their great advantage is that they do not need to be regularly monitored on a laboratory basis and are considered to be safer, especially to significant reduction of the risk of intracranial haemorrhage. Each drug in the group of direct oral anticoagulants has some specificity resulting from pharmacological properties or the results of registration studies, so it is possible to individually determine an optimal anticoagulation strategy. Older, respectively fragile patients are characterized by reduced body weight, limited renal function, and multiple comorbidities (associated with many co-medications). For a number of seniors, it is advantageous to use a reduced dose of these drugs. Consideration of benefit and risk is often complicated in elderly patients, but this should be repeatedly done during the therapy. Key words: anticoagulation therapy - apixaban - dabigatran - edoxaban - fragile patient - geriatrics - rivaroxaban.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
00:59Gene Therapy
01:26Group Therapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:22Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...